InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
15 hedge funds and large institutions have $118K invested in InVivo Therapeutics Holdings Corp in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
10% less capital invested
Capital invested by funds: $131K → $118K (-$12.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.34K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.35K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$251 |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$126 |
| 5 |
ITIM
Indiana Trust & Investment Management
Mishawaka,
Indiana
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$4.16K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$99 |
| 3 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$11 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1 |
| 5 |
WP
WealthPLAN Partners
Omaha,
Nebraska
|
-$1 |
NVIV Hedge Fund Activity: Q3 2023 in Review
15 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q3 2023, worth a combined $118K — down 9.5% from $131K a quarter earlier.
Fund positioning in NVIV was balanced in Q3 2023: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $9.34K. The largest seller was Renaissance Technologies, cutting an estimated $4.16K.
- 15 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $118K of InVivo Therapeutics Holdings Corp stock for Q3 2023, down 9.5% quarter-over-quarter.
- 3 funds opened new InVivo Therapeutics Holdings Corp positions in Q3 2023 and 3 closed out, a net change of 0 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q3 2023 was Geode Capital Management, an estimated $9.34K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q3 2023 was Renaissance Technologies, an estimated $4.16K sold.
Based on aggregated 13F filings for Q3 2023.